Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Document › Details

Oncopeptides AB. (3/8/23). "Press Release: Oncopeptides CSO Investigated for Violation of the Market Abuse Act".

Region Region Sweden
Organisations Organisation Oncopeptides AB (Nasdaq Stockholm: ONCO)
  Group Oncopeptides (Group)
  Organisation 2 Sweden (govt)
Products Product finance
  Product 2 Pepaxti® (Pepaxto®)
Persons Person Lindberg, Jakob (Oncopeptides AB 202301 CSO before CEO)
  Person 2 Gulliksen, Rolf (Oncopeptides 202102 Global Head of Corporate Communications)
     


Oncopeptides AB (publ), has been informed by the Swedish Economic Crime Authority that the CSO Jakob Lindberg has been arrested for a suspected violation of the Market Abuse Act (Sw. lag om straff för marknadsmissbruk på värdepappersmarknaden).

The Company does currently not have any additional information but will provide an update to the market when we have access to more information.


For more information, please contact:

Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28


This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-03-08 10:05 CET.


About Oncopeptides

Oncopeptides is a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US. On December 7, 2022, the FDA recommended that the Company voluntarily withdraw the US marketing authorization for Pepaxto.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.

   
Record changed: 2024-01-20

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Oncopeptides (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top